Interested in Collaborating?
For more information about our products or to send us information about your products and technologies, please email us email@example.com.
At Ocuphire Pharma, we’re interested in business development opportunities to in-license additional novel ophthalmic mid-stage clinical drug candidates as well as to partner with pharmaceutical companies for late-stage development, regulatory and commercialization collaborations in key global markets.
As part of the Rexahn merger transaction, several oncology product candidates developed by Rexahn had established licensing arrangements with BioSense and HaiChang. Prior Rexahn shareholders may receive certain cash payments from the grant, sale or transfer of rights to Rexahn’s existing intellectual property or pursuant to payments received by BioSense or HaiChang during a certain period following Closing on account of the Contingent Value Rights (CVR) Agreement. The CVRs will be issued pursuant to the CVR Agreement and Shareholder Representative Services LLC (“SRS”) will act as representative of holders of the CVRs.